Poland· PL-100444573
Oxlumo
A lumasiran product containing lumasiranum, registered in Poland by Alnylam Netherlands B.V.. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Lumasiran is registered in 12 of 19 countries.
Countries holding a registration under ATC A16AX18 (lumasiran), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Lumasiran · ATC A16AX18
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Lumasiranum
- Manufacturer
- Alnylam Netherlands B.V.
- Country
- Poland (PL)
- ATC code
- A16AX18
- ATC class
- Lumasiran
- Defined daily dose
- 2.3 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin08720165814138
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lumasiran in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandOxlumo 94.5 mg / 0.5 ml, InjektionslösungAlnylam Switzerland GmbH
- SpainOXLUMO 94,5 mg/0,5 ml SOLUCION INYECTABLEAlnylam Netherlands B.V.
- IcelandOxlumoAlnylam Netherlands B.V.
- SwedenOxlumo 94,5 mg/0,5 ml Injektionsvätska, lösningAlnylam Netherlands B.V.
- CanadaOXLUMOALNYLAM NETHERLANDS B.V.
- FranceOXLUMO 94,5 mg/0,5mL, solution injectableALNYLAM NETHERLANDS (PAYS-BAS)
- United KingdomOxlumo 94.5mg/0.5ml solution for injection vialsAlnylam UK Ltd
- NetherlandsOxlumo 189 mg/ml, oplossing voor injectieAlnylam Netherlands B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Oxlumo
- Liechtenstein · Oxlumo
- Norway · Oxlumo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cecb2e94-b57c-422e-a1d1-7eda3ab68217 GET /v1/drugs/cecb2e94-b57c-422e-a1d1-7eda3ab68217?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "94,5 mg/0,5 ml",
"packaging": "08720165814138 ¦ Rpz ¦ EU/1/20/1496/001 ¦ 138620\n1 fiol. 0,5 ml\n¦ UR/Z/4b/188/22 ¦ UR/Z/4b/025/21 - 08720165814138 ¦ UR/Z/4b/123/23 - 08720165814138 ¦ UR/Z/4b/162/24 - 08720165814138 ¦ UR/Z/4b/081/25 - 08720165814138 ¦ UR/Z/4b/004/26 - 08720165814138",
"substance": "Lumasiranum 94,5 mg/0,5 ml",
"common_name": "Lumasiranum",
"pl_product_id": "100444573",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about lumasiran.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.